Boditech Med Inc. (KOSDAQ:206640)

Market Cap	211.59B -39.8%
Revenue (ttm)	165.84B +15.0%
Net Income	25.99B -6.7%
EPS	1,200.41 -5.6%
Shares Out	20.34M
PE Ratio	8.66
Forward PE	n/a
Dividend	150.00 (1.43%)
Ex-Dividend Date	Mar 31, 2026

Volume	26,578
Open	10,700
Previous Close	10,510
Day's Range	10,170 - 10,700
52-Week Range	10,110 - 16,060
Beta	0.37
Analysts	n/a
Price Target	23,000.00 (+121.15%)
Earnings Date	Aug 12, 2026

About Boditech Med

Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testing for various parameters; ExAmplar, a compact real time PCR that detects virus/bacteria quantitatively or qualitatively using ready-to-use cartridges;...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 541
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206640

Financial Performance

In 2025, Boditech Med's revenue was 162.09 billion, an increase of 17.32% compared to the previous year's 138.16 billion. Earnings were 23.65 billion, a decrease of -13.23%.